Continual administration of semaglutide led to 15% reduction in body weight at 68 weeks, along with improvements in cardiovascular risk and overall physiological condition [9]
Salud Cardiovascular: Favorece la reduccin del colesterol LDL (colesterol malo) y el aumento del colestero HDL (colesterol bueno), lo que puede mejorar la salud cardiovascular
The FDA-approved injection sites for semaglutide include the abdomen, thigh, and upper arm
For some patients, the risk-benefit equation makes sense
Others reconstitute the 10mg vial, draw multiple doses into separate syringes, and freeze the pre-loaded syringes for later use
These hepatic benefits appear to result primarily from weight loss and improved metabolic parameters rather than direct liver effects